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 Summary
	   Frontotemporal	dementia	is	the	third	most	common	degenerative	condition	(after	Alzheimer	Disease	
and	Lewy	Body	Disease)	of	the	brain.	It	occurs	predominantly	after	the	age	of	40	and	usually	before	
the	 age	 of	 65,	with	 equal	 incidence	 in	men	 and	women.	Unspecific	 behavioral	 symptoms	 often	
lead	to	misdiagnosis	and	FTD	remains	undetected.	As	in	other	degenerative	dementias,	there	is	no	
specific	 tissue	marker;	 therefore,	 the	diagnosis	 is	 established	 in	vivo	on	 the	basis	 of	 clinical	 and	
radiological	 examinations.	 Structural	 and	 functional	neuroimaging	modalities	 are	most	useful	 in	
detection	and	differentiation	of	FTD	as	the	findings	are	specific	enough	to	be	considered	as	criteria,	
based	on	which	the	diagnosis	of	this	disorder	can	be	established.
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Background
Frontotemporal	dementia	 (FTD),	 in	 literature	also	 referred	
to	 as	 frontotemporal	 lobar	degeneration	 (FTLD),	 has	 simi-
lar	occurrence	to	the	Alzheimer’s	disease	 in	the	age	group	
younger	than	65	years	old	 [1].	 It	represents	clinically,	pat-
hologically	and	genetically	diversified	group	of	neurodege-
nerative	 states,	 in	which	 the	disease	process	 affects	with	
more	or	less	asymmetry	the	frontal	and/or	temporal	lobes.	
Regarding	the	neuropathological	lesions,	FTD	is	divided	to	
tauopathies	 and	 syndromes	without	 tau	protein	 aggrega-
tion	 in	brain.	As	 for	 genetics,	 FTD	 is	 also	heterogeneous.	
In	 about	 30-50%	 of	 cases	 FTD	 is	 familial	 and	 is	 usually	
inherited	 in	an	autosomal	dominant	way,	 including	small	
number	 of	 cases	 of	 fronto-temporal dementia with par-
kinsonism linked to chromosome 17	 (FTDP-17)	 caused	by	
tau	protein	 gene	mutation.	 In	 several	 families	 there	was	
also	a	link	with	chromosome	3	[2,	3];	however,	in	majori-
ty	of	non-tauopathy	FTD	cases	 the	genetic	background	 is	
	unknown.	
In	 clinical	 presentation,	we	mark	 out	 3	main	 syndromes	
depending	on	topography:	
•		frontotemporal	 dementia	 with	 dominating	 behavioral	
disorders,	also	referred	to	as	frontal variant FTD (fvFTD)
•		frontotemporal	 dementia	with	 dominating	 verbal	 disor-
ders,	also	referred	to	as	temporal variant FTD (tvFTD),	in	
other	words:	semantic	dementia	(SD)
•		progressive non-fluent aphasia	 (PNFA),	 which	 is	 least	
	frequent	
In	FTD	diagnosing,	not	only	the	presence	of	typical	clinical	
symptoms	 is	 important,	 but	 also	 the	 result	 of	 structural	
and/or	 functional	 neuroimaging	 examinations.	 They	 are	
one	 of	 the	most	useful	 diagnostic	methods	 for	 confirma-
tion	 of	 the	 diagnosis	 based	 on	 clinical	 image,	 as	well	 as	
for	 canceling	 out	 particular	 symptomatic	 causes	 of	 cog-
nitive	 disorders,	 such	 as	 tumors,	 chronic	 posttraumatic	
hematomas	 or	 dilatation	 of	 ventricular	 system	 in	 course	
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of	Hakim’s	syndrome.	These	examinations	are	also	essen-
tial	 for	 differentiation	 from	 vascular	 dementia,	 parti-
cularly	 caused	by	multiple	 lacunar	 ischemic	 focuses	 and	
Alzheimer’s	disease.	The	knowledge	about	possible	radio-
logical	lesions	that	occur	depending	on	the	clinical	variant	
of	FTD	is	also	important.	
Clinical picture
FTD	 is	one	of	 the	presenile	dementia.	The	disease	usually	
starts	between	the	age	of	50	and	70.	The	occurrence	 is	as	
equally	often	in	women	and	in	men.	
Frontotemporal dementia – frontal variant (fvFTD) 
The	beginning	is	often	delusive.	Disease	usually	lasts	for	10	
years	and	proceeds	slowly.	Initial	symptoms	are	often	asso-
ciated	with	changes	in	personality,	mood,	drive	and	behav-
ioral	disorders	[4].	Most	patients	are	brought	to	the	doctor	
by	 an	 alarmed	 family	 as	 then	patient	himself	 is	 unaware	
of	 the	disease.	Affected	 orbital-basal	 part	 of	 cortex	 of	 the	
frontal	lobe	causes	disinhibition,	lack	of	insight,	pathologic	
distraction	and	impulsiveness,	whilst	affected	anterior	part	
of	cingulate	gyrus	and	medial	part	of	the	cortex	of	frontal	
lobe	causes	lack	of	drive	leading	to	akinetic	mutism	on	an	
advanced	stage	[5].	Patients	can	either	be	motor	and	verbal-
ly	overexcited,	irritable,	with	uncontrolled	attacks	of	anger	
or	excessively	sentimental,	euphoric,	also	retreated,	passive	
and	 apathetic.	 Both	 of	 the	 behavioral	 patterns	 can	 occur	
alternatingly.
The	most	typical	behavioral	disorders	concern	social	behav-
ior	 (including	also	crimes	and	inappropriate	sexual	behav-
iors)	[6].	Stereotypic,	persevering	and	compulsive	behaviors	
are	 characteristic.	 Lack	 of	 empathy	 is	 one	 of	 the	 earliest	
symptoms.	 In	some	cases	on	a	 later	 stage	we	can	observe	
elements	 of	Klüver–Bucy`s	 syndrome	which	 is	 caused	by	
affected	 anterior	 parts	 of	 both	 temporal	 lobes	 (change	 in	
dietetic	 likings,	 usually	 to	 sweets,	 hyperorality,	 increase/
decrease	in	sexual	activity).
Language	 disorders	 consist	 in	 vocabulary	 deficits	 leading	
to	 anomia,	 with	 preserved	 understanding	 of	 speech	 and	
repeating.	
Frontotemporal dementia – temporal variant (tvFTD) – semantic 
dementia
The	atrophy	concerns	mainly	the	anterior	parts	of	temporal	
lobes	 and	 is	more	 or	 less	 symmetrical;	 at	 first,	 it	 affects	
anterior	part	of	the	left	temporal	lobe.	
What	attracts	most	attention	in	clinical	presentation	is	the	
deep	semantic	(acquired)	memory	disorders	and	loss	of	ver-
bal	memory.	At	 the	 same	 time	 the	 episodic	memory	 (con-
cerning	events	in	patient’s	own	life)	and	day	to	day	memo-
ry	are	usually	preserved.	When	the	right	temple	is	involved	
prosopagnosia	occurs-	it	can	affect	not	only	sight,	but	also	
other	senses,	e.g.	associating	voice	with	a	person	[7].	
One	 of	 the	 typical	 features	 is	 fluent	 speech	with	 tenden-
cy	 to	 loquacity,	 with	 simultaneous	 deficits	 in	 vocabu-
lary	 of	 low	 informational	 value	 (so-called	 empty	words).	
Difficulties	with	searching	names	dominate,	but	the	gram-
matical	structure	remains	relatively	correct.	Echolalia	is	a	
common	concomitant	symptom.	
Behavioral	disorders	manifest	early	and	are	similar	to	those	
described	 in	 fvFTD.	Lack	of	 the	ability	 to	understand	and	
express	emotions	is	a	typical	symptom	resulting	from	atro-
phy	of	the	right	amygdaloid	body	[8].	
Progressive non-fluent aphasia (PNFA)
The	 syndrome	 is	 etiologically	diversified;	 in	 about	 50%	of	
cases	 the	 diagnosis	 based	 on	neuropathological	 examina-
tion	 is	 the	Alzheimer’s	disease	 [9].	Brain	atrophy	 is	asym-
metric	 and	affects	 left	 temporal	 and	 frontal	 lobe.	Patients	
with	PNFA	present	 lack	 of	 speech	 fluency	with	preserved	
understanding.	Their	 utterances	 are	 grammatically	 incor-
rect,	with	dominating	 signs	of	 omission	and	mistaken	use	
of	 prepositions	 and	 paraphasia.	 They	 have	 difficulties	 in	
repeating,	 reading	and	writing.	At	 first,	 the	 leading	symp-
tom	 is	 selective	 verbal	 unspontaneity.	 Speech	 apraxia	 is	
connected	with	involvement	of	insula	[10].
Disordered	 speech	 is	 often	 a	 symptom	 isolated	 for	 a	 very	
long	time.	
Scheme	1.
Neurological symptoms 
Neurological	 symptoms	 include:	 at	 an	 early	 stage-	 often	
only	 deliberation	 symptoms,	 urinary	 incontinence	 is	 also	
possible;	at	a	later	stage	–	Parkinson	symptoms,	which	can	
be	asymmetrical	in	patients	with	PNFA	syndrome.
Extrapyramidal	syndrome	of	early	occurrence	suggests	cor-
ticobasal	 degeneration	 (CBD),	 especially	 in	 patients	with	
disordered	speech	[11].	
Scheme 1.		Examples	of	brain	atrophy	in	particular	types	of	FTD.	
The	regions	proper	for	FTD	are	outlined.
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Neuropsychological examination
In	 clinical	 variants	with	dominating	 speech	disorders	 the	
neuropsychological	 examination	 shows	 language	disorders	
typical	for	them.	Features	characteristic	for	fvFTD	include	
disorders	of	operational	memory,	speech	fluency,	abstracti-
ve	thinking	and	executive	functions.	The	deficit	 is	usually	
more	obvious	in	inertial	patients	than	in	those	excessively	
active	 and	disinhibited.	On	 the	 other	hand,	memory,	 per-
ception,	visual-spatial	analysis,	praxia	are	normal	or	relati-
vely	well	preserved.	
Differentiation
Alzheimer’s	disease
Usually	 requires	differentiation	with	FTD.	Occurs	 in	 senior	
age,	memory	disorders	are	the	first	symptom	and	behavioral	
disorders	manifest	later.	Also	the	ability	to	live	on	their	own	
is	 lost	 gradually,	with	 time,	 along	with	 growing	dementia,	
while	FTD	patients	lose	it	early	due	to	the	type	of	cognitive	
and	behavioral	disorders.	Stereotypies,	perseverances,	disin-
hibition,	 uncontrollable	 eating,	 low	 social	 consciousness,	
neglecting	oneself,	apathy	and	impulsiveness	are	often	men-
tioned	as	most	differentiating	between	FTD	and	AD	[12].
Pattern	 of	 cognitive	 disorders,	 different	 for	 every	 patient,	
can	also	be	helpful	in	differentiation.	Neurological	symptoms	
are	not	specific,	although	urine	incontinence	can	happen	ear-
lier	 in	FTD	than	 in	AD.	The	differences	between	neuroima-
ging	examinations	described	below	are	also	important.	
Vascular	dementia	(VaD)
Patients	 with	 VaD	 caused	 by	 multiple	 lacunar	 ischemic	
focuses	 can	manifest	 clinical	 symptoms	 similar	 to	 those	
typical	for	FTD.	Another	confusing	factor	is	the	slow	course	
(instead	of	fast)	of	the	disease	and	lack	of	stroke	in	clinical	
history.	The	 result	 of	CT	or	MR	 showing	vascular	 lesions	
determines	the	diagnosis.	
Treatment
No	drugs	are	known	to	influence	the	development	of	FTD	or	
modify	its	course.	Cholinergic	deficit,	unlike	in	Alzheimer’s	
disease,	 is	hardly	expressed.	Cholinesterase	inhibitors	pro-
ved	 to	 be	 ineffective	 in	 treating	 the	 disordered	 cognitive	
functions	and	behavioral	disorders	are	in	some	cases	inten-
sified	by	them.	
Difficulties	 in	neurotransmission	 in	 serotoninergic	 system	
observed	 in	FTD	are	 responsible	 for	 impulsiveness,	 irrita-
bility,	changes	in	mood	and	diet	routine.	Hence	there	were	
attempts	 to	 apply	 selective	 inhibitors	 of	 serotonin	uptake	
in	FTD	in	order	to	control	behavioral	disorders.	They	were	
open	examinations	performed	on	small	groups	of	patients.	
Fluoxetine,	 sertraline	 or	 paroxetine	 taken	 by	 11	 patients	
for	 3	 months	 gave	 improvement	 in	 disinhibition	 (6/9	
patients),	voracity	(5/9),	compulsion	(4/7)	and	depression	in	
9	patients	[13].	
Trazodon	 has	 a	 serotoninergic	 effect-	 it	 is	 an	 antagonist	
of	5HTa/2c	postsynaptic	receptor	and	antagonist	of	5HT1a	
receptor.	Lebert	and	Pasquier	(1999)	observed	the	influence	
of	trazodon	on	intensification	of	behavioral	disorders	mea-
sured	with	NPI	 in	14	patients	with	FTD.	After	4	weeks	of	
treatment	with	dose	of	150	mg	per	day	the	patients	showed	
lower	 intensity	of	 illusions,	aggression,	 fear	and	 irritabili-
ty.	After	 another	 2	weeks	when	patients	 took	 trazodon	 in	
dose	of	300	mg	per	day	additional	improvement	was	obser-
ved	considering	depression,	disinhibition	and	weird	motor	
behaviors	[14].	
In	clinical	practice	antiepileptic	drugs	(carbamazepine	and	
valproic	 acid)	 and	 antipsychotic	 drugs	 are	widely	used	 to	
control	 the	 FTD	 agitation.	 Due	 to	 the	 safety	 profile,	 the	
drugs	chosen	from	the	latter	group	should	be	drugs	of	the	
new	generation	[15].	
People	 taking	 care	 of	 FTD	patients	 are	 subject	 to	 no	 less	
burden	 than	 those	who	 look	 after	 AD	 patients,	 although	
some	believe	that	the	burden	is	even	bigger	for	FTD.	They	
require	 emotional	 support	 and	detailed	 education	 concer-
ning	the	course	of	disease,	what	helps	to	organize	the	care	
in	a	proper	way.	
Neuroimaging examinations 
1. Structural CT, MR
Structural	 FTD	 examinations	 show	 typical	 topography	 of	
atrophy	which	includes	a	more	or	less	symmetrical	selecti-
ve	atrophy	in	anterior	frontal	and/or	temporal	lobes	(fig.	1,	
2/3).	 Classic	 FTD	 image	 is	 presented	 as	 a	mixed	 atrophy	
of	 frontotemporal	 cortex	 with	 balloon-shaped	 dilatation	
Figure 1.	 	CT	scan	of	the	brain	reveals	widening	of	the	lateral	sulci	as	
a	reflection	of	cortical	atrophy	of	temporal	lobes.	Hypodense	
lacunar	lesion	within	deep	structures	of	the	right	hemisphere.
Male,	aged	59.	Secondary	education,	electrician,	does	not	
work	(retired).	4	years	ago	diagnosed	with	frontotemporal	
dementia:	•	lost	his	interests,	became	jesting,	stubborn,	
impulsive,	excessively	interested	in	sexuality,	•	started	to	
neglect	personal	hygiene,	•	attacks	of	voracity.	MMSE	26	
points.	Clock	test	10	points.	GDS	4.	BCRS	5	points	in	the	
category	„self-service”.	CDR	0,5/1.	Neurological	examination:	
deliberation	symptoms	on	the	right.
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Figure 4.	 	CT	scan	of	the	brain	reveals	cortical-subcortical		
atrophy	of	the	frontal	lobes.	Male,	aged	74.	Secondary	
education,	building	technician,	does	not	work	(retired).	
8	years	ago	diagnosed	with	frontotemporal	dementia.	
MMSE	29	points.Test	zegara	6	points.	GDS	3.	BCRS	
5	points	in	category	„self-service”.	CDR	0,5.	Neurologically:	
bilateral	grasp	reflex,	minor	bradykinesia	and	mask-like		
face,	gait	without	balancing	of	the	upper	limbs	but	with	
no	tremor	at	rest.
Figure 2/3.		CT	scan	of	the	brain	reveals	symmetric	atrophy	of	temporal	lobes	including	their	medial	parts	(MTL).	Discrete	frontal	lobes	atrophy.	
Continuation	of	examination	of	the	patient	from	Fig.	1.
Figure 5.	 	T2	FSE	axial	scan	reveals	general	cortical-subcortical	atrophy,	particularly	in	frontal	and	temporal	lobes.	Patient	aged	46	with	generalized	
cognitive	and	behavioral	disorders.	Major	difficulties	in	initiating	and	taking	simple	and	complex	actions.	Multiple	verbal	and	visual-spatial	
perseverance.	Unspontaneous	speech,	patient	with	articulation	problems,	replacing	speech	with	adequate	and	understandable	gestures.
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of	 frontal	 and	 temporal	 horns	 of	 lateral	 ventricles	 with	
accompanying	variable	level	of	gliosis	focuses	in	the	affec-
ted	lobes,	what	is	clearly	visible	in	FLAIR	images.	
Such	presentation	in	neuroimaging	examinations	is	so	typi-
cal	that	it	is	one	of	the	elements	that	confirm	the	diagnosis	
in	 clinical	 criteria	 of	 the	 disease	 [16].	On	 the	 other	 hand,	
it	 needs	 to	be	 emphasized	 that	 lack	 of	 atrophy	 in	 clinical	
suspicion	of	FTD	does	not	cancel	out	such	diagnosis.	
In	 frontal	 variant	 of	 FTD	 the	 atrophy	 is	 usually	 bilateral	
(fig.	4);	 in	PNFA	the	atrophy	is	 left-sided	and	asymmetrical,	
initially	 limited	 to	 the	 anterior	 temporal	 lobe	 and	 then	
involving	 the	 left	 (dominating)	 hemisphere,	while	 in	 SD-	
asymmetric	 atrophy	 of	 anterior	 parts	 of	 both	 temporal	
lobes	[17].	More	detailed	volumetric	examinations	in	mag-
netic	 resonance	 (voxel-based	morphometry)	 [18,	 19,	20]	
in	 fvFTD	 showed	atrophy	of	 orbital,	 dorsolateral	 frontal	
lobe,	cingulate	gyrus,	insula	and	dorsolateral	frontal	lobe,	
usually	visible	better	on	the	right	side.	In	PNFA	the	result	
was	 visualized	 better	 on	 the	 left	 and	 involved	 orbital	
gyrus	 of	 frontal	 lobe,	 cingulate	 gyrus,	 insula	 and	dorso-
lateral	 frontal	 lobe,	while	 in	 tvFTD	 the	 atrophy	affected	
orbital	 gyruses,	 anterior	 temporal	 lobe,	 amygdala	 and	
anterior	part	of	insula.
In	the	semantic	type	of	dementia	(fig.	5)	the	atrophy	is	often	
larger	 than	 in	 patients	with	Alzheimer’s	 disease	 and	 can	
involve	medial	structures	of	temporal	lobe,	but	usually	it	is	
more	symmetrical	and	is	accompanied	by	elevated	atrophy	
within	 the	 amygdala,	 pole	 of	 the	 temporal	 lobe,	 piriform	
gyrus	and	inferior-lateral	temporal	gyrus	[21].
2. Functional examinations: Single photon emission computed 
tomography (SPECT), positron emission tomography (PET)
Functional	 examinations	 visualize	 early	 the	 FTD	 disor-
ders	and	are	particularly	useful	in	differentiation	with	the	
Figure 6.	 	SPECT	scans	indicate	bilateral	profound	decrease	of	
perfusion/metabolism	in	both	temporal	lobes,	more	significant	
on	the	left	side.	Moderate	decrease	of	perfusion/metabolism	
in	frontal	lobes	bilateral,	more	significant	on	the	left	side	also.
Figure 7/8.		Single-voxel	H1MRS	reveals	abnormally	low	NAA	as	well	as	Cho	and	mI	expression	in	circumferential	parts	of	left	temporal	lobe.	H1MRS	
spectrum	profile	from	the	right	temporal	lobe	reveals	fewer	abnormalities	than	the	one	proceeding	from	the	contralateral	lobe.
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Alzheimer’s	disease.	Although	Knopman	et	al.	(2001)	did	not	
recommend	using	SPECT	and	PET	in	routine	diagnostics	of	
dementia,	Centers	for	Medicare	Services	(CMS)	have	agreed	
on	using	the	FDG-PET	for	differentiation	between	FTD	and	
Alzheimer’s	disease	in	doubtful	cases	[22].	
SPECT	examinations	show	typical	 selective	hypoperfusion	
of	 varied	 intensity	 in	 frontal	 lobes	 and	 anterior	 temporal	
lobes	(fig.6).	The	lesions	can	affect	all	the	mentioned	struc-
tures,	 concern	 only	 the	 frontal	 and/or	 temporal	 lobes,	 or	
can	be	marked	better	 on	 left	 or	 right	 side	 [23].	According	
to	some	authors,	the	differences	in	SPECT	(lower	perfusion	
in	frontal	lobes	and	/or	anterior	temporal	lobes	in	FTD,	and	
parietal	 lobes	 and	posterior	part	 of	 temporal	 lobes	 in	AD)	
allow	an	almost	100%	sure	diagnosis	[24].	
Examinations	 using	 FDG-PET	 show	 decrease	 in	 glucose	
metabolism	in	frontal	and/or	temporal	lobes	[25,	26].	It	also	
presents	 differences	 according	 to	 clinical	 variant	 of	 FTD.	
Diehl	et	al.	(2004)	found	in	frontal	FTD	symmetrical	hypo-
metabolism	of	 glucose	 in	 frontal	 lobes	with	 spared	motor	
cortex,	while	 in	 semantic	 variant	 the	 hypometabolism	of	
glucose	was	observed	only	in	the	whole	left	temporal	lobe	
and	pole	of	the	right	temporal	lobe	[27].
3. Metabolitic examinations- H1 MRS spectroscopy, single-voxel 
method
Magnetic	 Resonance	 Spectroscopy	 is	 an	 exponent	 of	
metabolic	processes	in	cerebral	tissue	by	showing	abnor-
mal	 spectrum	 from	 frontal	 and	 temporal	 parts,	 with	
NAA	 lowering	 (neuron	 indicator)	 and	mI	 concentration	
(gliosis	 indicators)	 (fig.	7/8).	 The	 spectra	 are	 similar	 in	
Alzheimer’s	 disease	 but	 their	 typical	 location	 is	 diffe-
rent.	In	some	cases,	mainly	with	coexistence	of	ischemic	
lesions,	higher	lactate	peaks	can	also	be	shown.	Ernst	et	
al.	 studied	spectra	 from	the	white	matter	of	 frontal	and	
temporo-parietal	part	and	found	that	in	FTD,	apart	from	
lower	NAA	and	higher	mI	in	some	patients,	there	was	also	
decrease	in	glutamates	(Glx)	and	increase	in	lactate	peak	
within	 the	 frontal	 lobes;	 in	Alzheimer’s	 disease	 similar	
spectra	 are	 present	 around	 temporo-parietal	 areas	 [28].	
Kantarci	 et	 al.	 having	 examined	AD,	FTD,	DLB	and	VaD	
patients	 using	 the	MR	 spectroscopy	 prove	 that	NAA/Cr	
is	most	 lowered	 in	patients	with	AD,	FTD	and	VaD.	The	
mI/Cr	 level	 is	 significantly	higher	 in	dementia	 characte-
rised	by	gliosis,	such	as	AD,	FTD,	while	Cho/Cr	is	higher	
in	cases	of	cholinergic	defect,	in	other	words:	in	AD	and	
DLB	[29].	
In	 spite	 of	many	 diagnostic	methods,	 the	 FTD	 diagnosis	
presents	various	difficulties.
Only	complex	imaging	diagnostics	and	cooperation	of	neuro-
logist,	 neuropsychologist	 and	 radiologist	 allows	 reaching	
the	final	diagnosis.	
Moreover,	 today	 we	 rest	 great	 hopes	 in	 molecular	
	imaging,	which	is	likely	to	enable	faster	and	more	precise	
diagnosing.
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